Accelagen’s medical team is growing, strengthening our capabilities in pharmacovigilance, medical writing, and clinical oversight for safer, smarter trials.

Accelagen is in an exciting phase of growth, with our medical team expanding to meet the increasing demands of clinical research. From pharmacovigilance to medical writing, three key experts are helping shape the company’s next chapter.

Bringing a wealth of experience across critical aspects of clinical trials, it’s time to meet Senior Drug Safety Associate Sadiqua Ansari, Medical Writer Jamal Khan, and Senior Medical Monitor Dr Adriana Ioan.

All things pharmacovigilance with Sadiqua Ansari

Under the umbrella of Regulatory Affairs, pharmacovigilance and drug safety plays a crucial role in making sure any new medicines we develop are safe as well as effective for patient use. Known for her self-confessed ‘meticulous’ approach and with a decade-long career in the industry, Sadiqua Ansari ensures the safety and efficacy of a wide range of pharmaceutical products tested at Accelagen. 

Since joining the team in April 2024, she has played a key role in bolstering  Accelagen’s safety management processes through expertise in adverse event reporting, risk management, and regulatory compliance. But what about the role has her most excited?

“I’m excited by the opportunity to work on innovative projects where we use advanced data analytics to predict and mitigate potential adverse reactions. Pharmacovigilance is constantly evolving, so there’s always something new to learn—whether it’s adapting to global regulations or exploring new methodologies.”

Relishing the opportunity to be part of an Australian-based CRO after moving from India in 2022, Sadiqua’s role continues to expand, as we do. With increasing opportunities for leadership and in-house development at Accelagen, she feels inspired to push the boundaries and hone her craft. 

“Working in a CRO means collaborating with a diverse team across different therapeutic areas, which keeps every day interesting. But most importantly, knowing that my work directly impacts the safety and efficacy of new medications is incredibly satisfying and motivating.”

The science of clear communication with Jamal Khan

Clinical trials generate vast amounts of data, but making that data clear, concise, and actionable is an art in itself. Medical Writer Jamal Khan joined Accelagen in September 2023, specialising in creating essential trial documentation, from clinical study protocols to regulatory reports and patient consent forms.

With a background in scientific research and drug delivery, not only does Jamal have a Bachelor of Pharmaceutical Science, but he has a PhD too—having studied the precipitation behaviour of poorly water-soluble drugs during the digestion of lipid-based formulations. Now that’s impressive! Able to translate complex clinical data into regulatory-compliant documentation, he shares:

“I’ve always liked writing and my background in research helps me to be able to summarise and write for different types of audiences. I’m passionate about writing important documentation for clinical trials in a way that is truly going to advance the medications that are available to patients.”

With the industry shifting towards increased outsourcing of medical writing to CROs, with talented professionals like Jamal on board, Accelagen is well-positioned as a key player in this space—offering expertly crafted documentation that streamlines approvals and enhances trial integrity.

Our medical monitoring eagle eye: Adriana Ioan

With over two decades of experience in medical monitoring and clinical oversight, as well as 16 years as a doctor in her native Romania, we are thrilled to have Adriana Ioan as part of our team, imparting her wisdom and experience on the “next generation of medical monitors”.

Having worked with major pharmaceutical companies like Pfizer, Roche, and GSK, Adriana has done it all—from leading oncology and haematology studies, to overseeing trial safety, and playing a pivotal role in drug development. Her deep understanding of what a successful clinical trial looks like, combined with hands-on global experience in both large-scale and emerging CROs, is a major asset to the Accelagen team.

She describes her role as Senior Medical Monitor as being primarily focused on patient safety, at the same time as working closely with Clinical Research Associates (CRAs), project managers, and data analysts to ensure trials meet rigorous safety and ethical standards. 

“We closely monitor patient data in real-time, spotting potential safety concerns before they escalate. If we notice patterns or risks, we take immediate action—whether that’s pausing recruitment, consulting investigators, or alerting sponsors.”

Looking for a role that allowed her to be more directly involved in problem-solving and decision-making, her transition from big pharma to a more hands-on CRO environment reflects a growing industry trend: smaller, highly specialised teams delivering more agile, responsive solutions for trial sponsors.

“I’ve worked in big pharma for years, but I was drawn to the flexibility of a smaller CRO. Here, I can be more hands-on, collaborate across departments, and help shape how we operate.”

Accelagen’s solution- and patient-first approach

In a rapidly evolving pharmaceutical and biotech landscape, sponsors need specialised expertise, faster trial execution, and seamless regulatory compliance.

By combining scientific rigour with a nimble, solution-driven approach, Accelagen is helping sponsors streamline processes, mitigate risks, and bring new treatments to market with confidence. Thanks to team members like Sadiqua, Jamal, and Adriana leading the charge, Accelagen’s future looks stronger than ever.

Get in touch with us today to learn more about our work and career opportunities.